Table 1 Studies in ARDS using proteomics platforms
From: Application of clinical proteomics in acute respiratory distress syndrome
Year | Proteomics methodology | Sample type | Number of subjects | Number of proteins identified | Reference |
|---|---|---|---|---|---|
2004 | 2DE-MALDI/TOF | Plasma and Edema fluid in ARDS and Plasma and BALF in non-smoking healthy controls | ALI/ARDS = 16, Controls = 12 | 300 distinct protein spots and 158 proteins identified. | Bowler [74] |
2006 | SELDI-TOF and 2DE + MALDI TOF/TOF | BALF | ARDS = 11, Healthy nonsmoking controls = 33 | Only differentially expressed proteins reported | De Torre [98] |
2006 | `Bottom-up’ proteomics with LC-MS/MS | BALF | ARDS = 3 | 226, 291 and 659 proteins for the three patients studied | Schnapp [35] |
2008 | 2DE-MALDI TOF/TOF | BALF | ARDS day 1 = 7 ARDS Day 3 = 8 ARDS day7 = 5 | 991 protein spots seen. Only 80 protein spots analyzed by MS which represented 37 unique proteins | Chang Martin [38] |
2013 | MALDI TOF/TOF | Pooled plasma | Direct lung injury = 6, Indirect lung injury = 5, healthy controls = 15 | 132 proteins | Chen [90] |
2014 | iTRAQ Orbitrap LC-MS/MS | Pooled BALF | Early phase ARDS survivors = 7 Early phase ARDS non-survivors = 8 Late phase ARDS survivors = 7 | 724 proteins identified, 499 proteins quantified | Bhargava [36] |